“Liquid biopsy” assays of circulating tumor cells (CTCs) should be conducted using arterial rather than venous blood specimens, according to a small study of 17 patients with metastatic uveal melanoma.
Skin Cancer / Melanoma Targets
The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for treating patients with BRAF V600 wild-type unresectable or metastatic melanoma.
Patients whose metastatic melanoma responded to pembrolizumab (Keytruda) immunotherapy had higher baseline frequencies of circulating immune T cells positive for CD8, programmed cell death protein 1 (PD-1), and Bim.
A new nationwide clinical trial comparing two groups of drugs for treating melanoma is marking a new era in the treatment of melanoma and how best to use the latest molecular tools.
The US Food and Drug Administration (FDA) have granted a priority review for Merck’s anti-PD-1 agent pembrolizumab (Keytruda) as a first-line treatment of advanced melanoma, the company announced.
Interleukin (IL)-2 combined with imiquimod and topical retinoid therapy may help improve outcomes in melanoma patients with cutaneous metastases, according to a study published online August 11, 2015 in the Journal of the American Academy of Dermatology.
A major step is now occurring in the advancement of precision medicine in the treatment of cancer. A record number of cancer patients are now being enrolled in a trial that is like none other before and marks a new era in treating cancer.
Oncologists now have a new tool for treating locally advanced basal cell carcinoma. On July 24, 2015, The US Food and Drug Administration (FDA) approved sonidegib (Odomzo) to treat patients with this type of cancer after it has recurred following surgery or radiation therapy.
A new quantitative, blood-based test to identify BRAF-mutated melanoma tumors is now available according to the test’s manufacturer, Biocept, Inc.
This slide show provides information on the present and future of targeted therapies and immunotherapies based on a report from the IMS Institute for Healthcare Informatics.